The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1471
June 22, 2015
View Complete Issue         Table of Contents 2019 
Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
June 22, 2015 (Issue: 1471)
The FDA has approved droxidopa (Northera – Lundbeck) for oral treatment of adults with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Droxidopa (Northera) for Neurogenic Orthostatic Hypotension
Article code: 1471c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.